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OBJECTIVES To explore existence and characteristics of national and local medication error 
reporting systems (MERSs), and to assess perceptions of national medication safety (MS) experts of a 
good and effective MERS and barriers to reporting.  
DESIGN A descriptive cross-sectional on-line survey.  
SUBJECTS AND SETTING 32 national MS experts identified from 88 member countries of the 
International Pharmaceutical Federation (FIP) and 3 additional countries.  
OUTCOME MEASURES The existence and characteristics of national and local MERSs in the 
participating countries, perceptions of a good and effective MERS, and perceptions of barriers to 
reporting. 
RESULTS 16 out of 32 identified national MS experts participated in the study, each from a different 
country (response rate 50%). A national (n=8) or local (n=5) MERS existed in 11 countries and did not 
exist in 5 countries. The most common feature of MERSs was confidentiality of reported information. 
The most often mentioned characteristics of a good and effective MERS were learning from errors, a 
non-punitive approach in reporting, and ease of use. Major barriers were blame culture, lack of time, 
lack of training and coordination of reporting.  
CONCLUSIONS The blame culture, lack of time, training and coordination of reporting continue to be 
the major barriers to reporting. Learning from errors and a non-punitive approach to reporting were the 
most important features of a good and effective MERS. Difficulties to identify national MS experts 
indicate a need for establishing national and international networks for MS experts for information 
sharing. 
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INTRODUCTION 
 
Medication errors (MEs) are the most common single cause of an error in healthcare (HC).[1] Despite 
this and the evidence supporting incident reporting as a leading initiative to improve medication safety 
(MS),[1-4] medication error reporting systems (MERSs) are still rare in HC systems.[3] However, some 
countries have established such systems at national or local levels to record MEs, to facilitate learning 
from factors related to MEs, and to take actions to prevent errors from happening.[4-9] Previous 
studies have often concentrated on exploring errors and error rates reported to MERSs in developed 
countries, mainly in United States and United Kingdom, instead of describing how these systems 
could be developed and implemented.[6,7,10,11] In addition, no previous studies have looked at the 
different characteristics of MERSs across countries. Nevertheless, such information could be helpful 
for countries without a system or those willing to improve their existing MERS. Moreover, it would be 
valuable to gather information from different types of countries as countries vary in terms of HC 
systems and socio-economic environments.[12,13]  
 
This study was conducted to describe the state of MERSs in developed and developing countries and 
to explore characteristics of these systems. The specific objectives were to explore the existence and 
characteristics of national and local MERSs, and to identify perceived attributes of a good and 
effective MERS and barriers to reporting. 
 
 
METHODS 
 
Study design, subjects and setting 
 
This was a descriptive cross-sectional on-line survey targeted to national MS experts knowledgeable 
about MERSs in their countries. To identify these experts, the network of the International 
Pharmaceutical Federation (FIP) was used. The FIP is a global umbrella organisation for pharmacy 
practice and pharmaceutical sciences which has patient safety (PS) as one of the strategic focus 
areas. [14,15] It collaborates closely with the World Health Organization (WHO).  
 
In total, 120 FIP member organisations in 88 countries were contacted through the FIP Headquarters 
requesting support in reaching MS experts in their respective countries (Figure 1). The FIP also 
contacted 20 other organisations known through their networks inside and outside the member 
countries, giving 91 contacted countries. The countries were divided into developed and developing 
countries based on the United Nations’ Human Development Index (HDI) which is a measure of a long 
  
5 
and healthy life, knowledge, and a standard of living.[12] Additional WHO statistics  were collected on 
the quality and capacity of HC of these countries.[13] This information was used to test the 
representativeness of the participating countries of the wider sampling frame. An ethical approval was 
sought and obtained through the University of Bath ethical review process prior to study initiation. 
 
Development, piloting and administration of the questionnaire 
A self-completed on-line questionnaire was developed using the literature on recommended 
characteristics of a MERS, characteristics of the existing national and local MERSs, and challenges 
encountered in medication error reporting (MER) practices.[3,16-18] The questionnaire comprised a 
set of 29 structured questions divided into 3 sections. Section I explored the background information 
on respondent countries and individual respondents. Subsequently, the respondents were directed to 
Section II (countries with a national or local MERS), or to Section III (countries with no MERS). 
 
The questionnaire was piloted through the WHO Alliance for Patient Safety and the FIP Working 
Group on Patient Safety for content and face validity. After the pilot and revisions, a link to the final 
questionnaire and the cover letter were emailed to the identified MS experts in spring 2007 and 2 
reminders were sent to non-respondents at fortnightly intervals.  
 
Data analysis 
The data were received in Excel format and entered onto an SPSS 15.0 database for statistical 
analysis. The quality of data entries was ensured. Descriptive statistics using appropriate parametric 
and non-parametric tests were employed.[19,20]  
 
 
RESULTS 
 
Participating countries and respondents 
 
Contact details of 32  MS experts working for national or other organisations involved in PS and MS in 
26 countries (19 developed and 4 developing countries; unknown for 3) were received from the 
informants in spring 2007 (Figure 1). This implies a lack of international network in MS. Overall, 16 
experts gave a usable response to the questionnaire, representing countries in Africa (n=3), 
Australasia (n=3), Europe (n=9) and North-America (n=1), giving a response rate of 50% (Table 1). 
The respondents represented a wide range of national and local organisations involved in improving 
PS and MS and quality of HC (Table 2). The countries of the respondents represented well the 91 
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sampling frame countries in terms of the variables selected to describe HC and the state of 
development (Table 3). The only statistically significant difference was found in the number of nurses 
per thousand inhabitants. 
 
 
 
 
 
Figure 1 Recruitment process of the 16 participating medication safety (MS) experts who responded the 
questionnaire on medication error reporting systems in their countries. FIP = International Pharmaceutical 
Federation. 
  
20 additional 
organisations 
(3 countries)  
120 FIP member 
organisations 
(88 countries) 
140 organisations 
(91 countries) 
32 MS experts  
(26 countries) 
16 participating MS 
experts 
(16 countries) 
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Table 1 Existence and type of medication error reporting systems 
(MERSs) in the countries of the participants (N=16). 
MERS  Countries 
National system 
Medication error reporting system Canada* 
  Japan* 
  Sweden* 
Integrated in an adverse event reporting system Norway* 
  Zambia ** 
Local system 
Within a community setting Australia* 
In community and hospital setting Czech Republic* 
A shared system between several hospitals Finland* 
Within a hospital setting Hungary* 
Setting not known Austria* 
  Rwanda ** 
No system   
  Ghana ** 
  India* 
  Kosovo* 
  Latvia* 
  Serbia* 
Footnote: *Developed country;  **Developing 
country.   
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Table 2 Organisations of the respondents (N=16) 
Organisations of the respondents n 
National Organisation   
Professional Body 4 
Regulatory Body 4 
Government and Professional Body 2 
Independent Non-Profit Organisation for Patient Safety 1 
National Corporation 1 
Local Organisation   
Educational Institution 3 
Hospital 1 
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Table 3 The characteristics of the participating countries (n=16) and the sampling frame countries (N=91), and the representativeness 
of the participating countries of the sampling frame countries. 
Characteristic 
Sampling frame countries 
(N=91) 
Participating countries 
(N=16) 
Non-participating countries 
(N=75) 
P-value 
With statistics 
available (n) 
Mean 
With statistics 
available (n) 
Mean 
With statistics 
available (n) 
Mean 
Population 75 16 760 920 13 11 959 154 62 17 767 742 NS § 
Healthy life 
expectancy (years) 
         
Men 89 59.07 15 61.03 74  58,68 NS † 
Women 89 62.06 15 63.00 74  61,87 NS † 
Expenditure on health          
(USD) for 
healthcare/(USD) 
GNP*100% ** 
88 6.67 15 7.48 73  6,50 NS ‡ 
Tot. Expenditure on 
health/capita (USD) 
88 948.18 15 1 527.93 73 829,05 NS § 
Human resources/ 
1000 inhabitants 
         
Physicians 89 1.76 14 2.17 75 1,68 NS § 
Nurses 89 4.22 14 7.35 75 3,64 0.011 § 
Pharmacists 80 0.40 13 0.55 67 0,36 NS § 
Human Development 
Index (HDI) 
85 0.754 14 0.804 67 0,744 NS † 
§ non-parametric Mann-Whitney U test; † non-parametric Chi Square test; ‡ parametric t-test (exact, 2-tailed); *outliers and extreme 
values removed; ** Gross National Product; Statistics from World Health Organization and United Nations.[12,13] 
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Existence of MERSs and their characteristics 
A MERS existed in 11 countries: 9 were in developed countries and 2 in developing countries (Table 
1). 5 countries did not have a MERS. 8 respondents provided further information on 5 national and 3 
local MERSs (Table 4). The most common characteristic of a MERS was confidentiality of reported 
information (6/8) (Table 4). The most common characteristics of national MERSs were: the MERS is 
provided and maintained by one national organisation (4/5); it is an integral part of a PS reporting 
system (4/5); it provides confidentiality of reported information (4/5); and it allows all healthcare 
professionals (HCPs) to report errors (4/5). On the other hand, all the local systems were reported to 
be easy to use (3/3), available electronically (3/3), allowed reporting of both potential and actual errors 
(3/3), and provided feedback on results of error analysis for those involved in reporting (3/3). 
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Table 4 Characteristics of the national and local medication error reporting systems (MERSs) in participating 
countries with a MERS and which provided further information (8/16). The characteristics are presented 
according to their frequency of appearance in national MERSs. 
Characteristic 
Type of MERS 
National system Local system 
Canada Japan Norway Sweden Zambia Australia 
Czech 
Republic 
Finland 
The MERS provides confidentiality 
of reported information 
X X   X X X   X 
The MERS is provided and 
maintained by one national 
organisation 
X X X X   X     
The MERS is an integral part of a 
patient safety reporting system 
  X X X X     X 
The MERS allows all healthcare 
professionals to report errors 
X   X X X     X 
The MERS provides feedback of 
results of error analysis for those 
involved in reporting 
X X   X   X X X 
The MERS is paper based     X X X X X   
The MERS provides opportunity for 
error data analysis 
X X   X   X X   
The MERS provides an opportunity 
for evaluating causes of errors (e.g. 
root cause analysis) 
X X   X   X X   
Reporting of errors through the 
MERS is mandatory 
  X X X   X     
The MERS is available in electronic X X       X X X 
The MERS includes reporting of 
both potential and actual errors 
X   X     X X X 
Reporting of errors through the 
MERS is voluntary 
X       X   X X 
The MERS uses a non-punitive 
approach to reporting 
X X       X   X 
The MERS provides a choice of 
reporting anonymously 
X X         X X 
The MERS produces 
recommendations and guidelines 
for improving medication safety 
X     X   X X   
The MERS is an independent 
reporting system dedicated for 
medication error reporting 
X X       X     
The MERS provides 
patients/consumers an opportunity 
to report errors 
X       X       
The MERS is easy to use X         X X X 
The MERS is quick to use X           X X 
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Perceived characteristics of a good and effective MERS and barriers to reporting 
 
The most often mentioned characteristics of a good and effective MERS were: the MERS should 
provide an opportunity for evaluating causes of errors (9/16); have a non-punitive approach to 
reporting (8/16); provide feedback of results of error analysis for those involved in reporting (8/16), and 
be easy to use (8/16) (Table 5).  
 
Fear of consequences was the most commonly mentioned barrier to reporting (13/16) (Table 5). Other 
frequently mentioned barriers were culture of blame (8/16), a lack of training for reporting (8/16), a lack 
of time for reporting (8/16), and a lack of organisational leadership and support (7/16).  
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Table 5 Perceived characteristics of a good and effective medication error reporting system (MERS) 
and perceived barriers to reporting by the 16 respondents of the study.  The respondents were asked 
to indicate five characteristics that they perceived as important in a good and effective MERS and five 
characteristics being the major barriers for reporting medication errors  (structured questions with 
given alternatives were used).* 
Characteristic of a good and effective MERS n 
The MERS provides an opportunity for evaluating causes of errors (e.g. root cause 
analysis) 
9 
The MERS uses a non-punitive approach to reporting 8 
The MERS provides feedback of results of error analysis for those involved in reporting 8 
The MERS is easy to use 8 
The MERS provides opportunity for error data analysis 7 
The MERS produces recommendations and guidelines for improving the medication 
safety 
7 
The MERS provides patients/consumers an opportunity to report errors 7 
The MERS provides confidentiality of reported information 6 
The MERS is provided and maintained by one national organisation 6 
The MERS is an integral part of a patient safety reporting system 4 
Reporting of errors through the MERS is voluntary 4 
Reporting of errors through the MERS is mandatory 4 
The MERS allows all healthcare professionals to report errors 3 
The MERS is available in electronic format 2 
The MERS is an independent reporting system dedicated for medication error reporting 1 
The MERS provides a choice of reporting anonymously 1 
The MERS includes reporting of both potential and actual errors 1 
The MERS is quick to use 0 
The MERS is paper based 0 
Barriers to reporting medication errors n 
Fear of consequences 13 
Culture of blame 8 
Lack of training in medication error reporting for healthcare professionals 8 
Lack of time for reporting 8 
Lack of organisational leadership and support 7 
Lack of legal protection for individual healthcare professionals who have made an error 6 
Lack of relevant guidelines and policies on medication error reporting 6 
Lack of understanding why reporting is needed 6 
Concern that no beneficial action will follow 5 
Non-anonymous reporting 5 
Perceived to be bureaucratic 3 
Lack of healthcare staff 3 
Lack of financial resources 2 
Footnote: * 1 country reported 9 characteristics instead of 5 and another 4 instead of 5.   
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DISCUSSION  
 
Key findings 
The study was stimulated by the current international need for developing MERSs and sharing 
experiences from existing systems.[1,3,21,22] Despite the current trends in shifting away from the 
blame culture in HC, the fear of consequences and the blame culture were still seen as the major 
barriers to reporting MEs. However, the non-punitive approach to MER was perceived as an important 
characteristic of a good and effective MERS. In practice the situation may still be different as only half 
of the countries reported non-punitiveness as a characteristic of their existing MERS, which may or 
may not be promoted by national legislation. Other barriers were a lack of training in MER for HCPs, a 
lack of time for reporting and a lack of organisational leadership and support. These findings support 
the current understanding that successful implementation of a MERS should focus on changing the 
blame culture and promoting learning from errors among practitioners and other stakeholders involved 
in MER.[17,23-25] To overcome these barriers to MER, well-coordinated, long-term collaboration 
between authorities, HCPs and educational organisations may be required, as well as potential 
changes in legislation.  
 
The most common characteristics of MERSs were confidentiality of reported information and feedback 
of results of error analysis for those involved in reporting. These characteristics indicate that the 
majority of these national and local MERSs have been designed to include activities which provide 
opportunities for learning from errors and affecting the blame culture. However, confidentiality of the 
system does not exclude the chance of a HCP being punished for committing an error.  
 
Interestingly, the most common characteristics of the national and local MERSs differed. It seems that 
the focus in national MERSs may be more in feasible nationwide reporting and learning, whereas local 
MERSs seem to be more focused on the feasibility of the reporting from the perspective of those 
reporting. To enable national MER, the system might need to be provided and maintained by one 
national organisation and to be an integral part of a PS reporting system enabling all HCPs to report 
errors. However, for feasible reporting, the characteristics of both national and local MERSs may need 
to be included in the MERS.  
 
The findings were in line with the previous studies promoting learning from errors:[1,26,27] the survey 
showed that learning from errors was strongly emphasised as  the most frequently reported 
characteristics of a good and effective MERS. This characteristic was also reported to be present in 
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most of the existing systems indicating progress in seeking systems based strategies to prevent 
MEs.[28] Consequently, the lessons for countries developing MERSs would be that learning should 
follow reporting: it was perceived that a MERS should provide an opportunity for error data analysis 
and evaluating the causes of errors as well as providing feedback of error analysis for those involved 
in reporting. The MERS should also produce recommendations and guidelines for improving MS at 
national and local levels. These activities might also contribute to understanding why reporting is 
needed and to ameliorate concerns of a lack of follow up after reporting, both of which were indicated 
as barriers to reporting. There were also other relationships between characteristics of a good and 
effective MERS and reported barriers. If training on reporting was implemented it would aid removing 
barriers to reporting which are due to insufficient training. If the MERS was easy to use, it might 
reduce barriers related to a lack of time for reporting. 
 
Access to MS experts knowledgeable about MERSs in their countries proved to be the most 
challenging and time consuming part of the study. Despite the wide FIP networks and the help of the 
national professional pharmaceutical organisations, under one fifth of the contacted countries provided 
this information. This may be due to a lack of knowledge on MS and experts among the contacted 
organisations, indicating that PS and MS might be not nationally coordinated in many countries as 
recommended.[3] The findings also suggest that the international network for MS experts does not 
exist currently. When creating approaches to reduce MEs, such a network would be essential as it 
facilitates effective experience sharing on practices improving quality and safety of HC systems. As 
MERSs and reporting practices are under constant development,[29] there is a need for further 
research to explore the progress of these activities.  
 
Limitations   
 
The low number of respondent countries limits generalisability of the survey findings.[19] The 
response rate may have been influenced by the low number of countries which actually have a MERS. 
This, however, increases the need of disseminating information on the existing systems. Providing the 
questionnaire only in English may have contributed to the low response rate, as well as previously 
discussed challenges in accessing national MS experts. Furthermore, the recruitment of potential 
respondents was dependent on the informants in the national pharmaceutical organisations contacted 
by the FIP. Despite the low number of respondents, those who responded were able to provide 
detailed information on the MERS in their country. Additionally, the pioneering countries in MERSs 
such as United States and United Kingdom were missing from the data. 
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Conclusions  
 
The blame culture, a lack of time, training and coordination of reporting continue to be the major 
barriers to reporting MEs and need to be targeted by continuous actions. In a good and effective 
MERS learning from MEs is the most important feature together with a non-punitive approach to 
reporting. The study indicates that national and local MERS may have different functions and 
characteristics that need to be taken into account when developing these systems. Further research is 
needed to learn more about these characteristics and to explore how MERSs and MER practices have 
developed and what have been the success factors, enabling factors and best practices for reporting. 
There is also a strong need for establishing international network for MS experts for information 
sharing. 
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